

UPDATES ON APPROACHES TO ACCEPTABLE INTAKES OF NITROSAMINE DRUG SUBSTANCE RELATED IMPURITIES (NDSRIS) AND BIOEQUIVALENCE ASSESSMENT FOR REFORMULATED DRUG PRODUCTS

Day 1 Session 2A: NDSRIs: Risk Factors of Formation, Confirmatory Testing, and Risk Mitigation

<i>Introductions:</i>	Andre Raw, PhD Dan Snider, PhD	Associate Director, Science and Communication, OPQA I, OPQ, FDA Head of Global Quality Compliance, Viatris
<i>Presenters:</i>	David Keire, PhD Martha Essandoh, PhD Ian Ashworth, PhD Dan Berger, PhD Joerg Schlingemann, PhD	Office Director, OPQR, OPQ, FDA Postdoctoral Research Fellow, DPQR V, OPQR, OPQ, FDA Principal Scientist, Chemical Development, PT&D, AstraZeneca Senior Biologist, OPQA I, OPQ, FDA Director and Principal Expert, EMD Serono, Healthcare Quality Unit, Merck
<i>Moderator:</i>	Andre Raw, PhD Dan Snider, PhD	Associate Director, Science and Communication, OPQA I, OPQ, FDA Head of Global Quality Compliance, Viatris
<i>Panelists:</i>	David Keire, PhD Martha Essandoh, PhD Ian Ashworth, PhD Dan Berger, PhD Joerg Schlingemann, PhD Martin Ehlert, PhD	Office Director, OPQR, OPQ, FDA Postdoctoral Research Fellow, DPQR V, OPQR, OPQ, FDA Principal Scientist, Chemical Development, PT&D, AstraZeneca Senior Biologist, OPQA I, OPQ, FDA Director and Principal Expert, EMD Serono, Healthcare Quality Unit, Merck Vice President, Global API R&D, Apotex Inc.